Addex shareholders back all board proposals at 2026 annual meeting

Addex Therapeutics announced on June 30, 2026 that its shareholders backed every item put forward by the board of directors at the company's 2026 Annual General Meeting, with a large majority of votes cast, representing 29.35% of the company's outstanding capital.¹

Shareholders signed off on the annual report, the consolidated financial statements and the annual financial statements for the year 2025, the appropriation of the results as well as the compensation report, with the compensation vote held on a consultative basis.¹ Motions on compensation for the board of directors and executive management were also approved, and discharge was granted to both groups for their work during 2025.¹

On board composition, Dr. Vincent Lawton was re-elected as a director and chairman as well as a member of the compensation committee, Dr. Raymond Hill was re-elected as a director and compensation committee member, and Dr. Roger Mills, Tim Dyer, Jake Nunn and Dr. Isaac Manke were all re-elected to the board.¹ BDO SA was re-elected as auditor for the 2026 business year, and Robert P. Briner was re-elected as independent voting rights representative through the 2027 Annual General Meeting.¹

Shareholders also approved changes to the company's Articles of Association covering the capital band and conditional share capital, according to the release. Addex noted that full agenda details are posted in the general meetings section of its website.

The company describes itself as a clinical-stage biopharmaceutical firm working on small molecule allosteric modulators for neurological disorders. It said its lead candidate dipraglurant, an mGlu5 negative allosteric modulator, is being evaluated for potential use in recovery from brain injury, including after stroke or traumatic brain injury.¹ The release also recapped partnered and internal pipeline programs, including work by partner Indivior and Addex's own GABAB PAM program for chronic cough, plus its equity stakes in Neurosterix US Holdings LLC and Stalicla.